DXR – Daxor Corporation Announces Rise in Kit Sales

In reporting its annual results for its medical device division, Daxor cited a 25% rise in kit sales related to cardiology use as well as an uptrend in overall kit sales for blood volume usage across all indications.

In addition, the Company sold a new BVA-100 system to Self Regional Healthcare of Greenwood, South Carolina for use in their cardiology department following a successful pilot program.Blood volume measurement is a fundamental tool for accurate diagnosis and treatment in a variety of medical and surgical conditions, such as congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia, as well as additional conditions.

Daxor Corporation manufactures and markets the BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit. The BVA -100 is the only FDA-cleared instrument which quantifies blood volume with 98% accuracy with results available in under an hour. Over a dozen widespread medical conditions benefit from accurate volume assessment to guide therapy including heart failure and ICU use, the company has focused on sales in these areas. Related () – Source TradeTheNews.com

News: Announces 25% rise in kit sales, new device sale, and filing of Form N-CSR for 2017

Time: Thursday, March 08, 2018 14:51

Notes: In addition, the Company sold a new BVA-100 system to Self Regional Healthcare of Greenwood, South Carolina for use in their cardiology department following a successful pilot program.Blood volume measurement is a fundamental tool for accurate diagnosis and treatment in a variety of medical and surgical conditions, such as congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia, as well as additional conditions.Daxor Corporation manufactures and markets the BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit. The BVA -100 is the only FDA-cleared instrument which quantifies blood volume with 98% accuracy with results available in under an hour. Over a dozen widespread medical conditions benefit from accurate volume assessment to guide therapy including heart failure and ICU use, the company has focused on sales in these areas. - Source TradeTheNews.com

Intraday Maximum Change: $3.149 - 44.5% Minutes After: 26

Latest Quote: 7.63 Change Since: $3.7022 - 48.52% Days Since: 45

Snapshot of company's key stats at the time of the event

Market Cap: 22,459,664 Shares Outstanding: 3,737,049 Float: 397,702

Day's Short Interest: 41 Short Ratio: 0.02%

Institutional Ownership: 3.1% Insider Ownership: 88.1%

DXR - Daxor Corporation

Sector: Healthcare - Industry: Medical Instruments & Equipment

Daxor Corp is a US-based biotechnology company which provides original medical equipment for medical personnel. It manufactures the BVA-100 Blood Volume Analyzer that provides a rapid direct measurement of a patient's blood volume.

Leave a Reply

Your email address will not be published. Required fields are marked *